GlaxoSmithKline has partnered up with Dr. Reddy's Laboratories in a deal that will allow GSK to sell Dr. Reddy’s generic pharmaceutical products in emerging markets. The targeted countries include China. GSK has the right to select products from Dr. Reddy’s portfolio of over 100 branded pharmaceuticals, which GSK will distribute through its established sales infrastructure. More details...

Stock Symbols: (NYSE: GSK) (NYSE: RDL)